Versigent (NYSE:VGNT – Get Free Report) has received a consensus recommendation of “Buy” from the thirteen brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold recommendation, nine have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $49.6667.
VGNT has been the subject of several analyst reports. Zacks Research upgraded shares of Versigent from a “hold” rating to a “strong-buy” rating in a research report on Thursday, July 2nd. Evercore restated an “outperform” rating and issued a $60.00 price objective on shares of Versigent in a report on Monday, May 18th. Argus set a $50.00 price objective on shares of Versigent in a research note on Tuesday, July 21st. Morgan Stanley initiated coverage on shares of Versigent in a research note on Friday, May 8th. They issued an “overweight” rating and a $51.00 price objective on the stock. Finally, BNP Paribas Exane began coverage on shares of Versigent in a report on Tuesday, April 28th. They set an “outperform” rating and a $41.00 target price for the company.
Get Our Latest Analysis on VGNT
Versigent Price Performance
Further Reading
- Five stocks we like better than Versigent
- 3 Fixed-Income ETFs Show Why Yield Is Only Part of the Income Story
- AbbVie Quietly Solved Its Biggest Problem—Now What?
- Rio Tinto’s Results Make the Case for Looking Beyond Tech in the AI Trade
- Strategy’s Structural Strength: Hidden in a $8 Billion Illusion
Receive News & Ratings for Versigent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versigent and related companies with MarketBeat.com's FREE daily email newsletter.
